Video

Dr. Ip on Next-Generation Sequencing in Myeloid Neoplasms

Author(s):

Andrew Ip, MD, discusses the use of targeted next-generation sequencing in detecting chromosomal structural abnormalities in patients with myeloid neoplasms.

Andrew Ip, MD, chief, Outcomes and Value Care Division, member, Division of Lymphoma, John Theurer Cancer Center, Hackensack Meridian Health, discusses the use of targeted next-generation sequencing (NGS) in detecting chromosomal structural abnormalities in patients with myeloid neoplasms.

In a study of the reliability of targeted cell-free DNA (cfDNA) NGS in predicting chromosomal abnormalities in patients with myeloid neoplasms, Ip and colleagues found that liquid biopsy with targeted NGS is an accurate way to detect chromosomal structural abnormalities in myeloid neoplasms when compared with samples from bone marrow biopsies. When classified by prognostic classes, the investigators observed a 100% concordance in cytogenetic abnormalities between cfDNA NGS data and cytogenetic data.

This study looked at copy number variation, or cytogenetic differences, in the blood samples, with the goal of risk stratifying patients to understand whether peripheral blood tests can replace more invasive testing, Ip says. Findings showed that cfDNA-targeted NGS was sensitive enough to identify myeloid neoplasms and lymphoid neoplasms in many patients, Ip explains.

An important limitation of DNA mutation testing is that it doesn’t detect some rare isolated chromosomal abnormalities, Ip notes. In this study, for instance, deletion 5q, a mutation that does not appear on a broad NGS panel, was not detected with cfDNA-targeted NGS, Ip says. However, most patients being tested for myelodysplastic syndrome will have a molecular mutation profile that NGS testing can detect, Ip concludes.

Related Videos
Yair Lotan, MD, UT Southwestern Medical Center
Alan Tan, MD, Vanderbilt-Ingram Cancer Center
Alex Herrera, MD
Roy S. Herbst, MD, PhD
Sheldon M. Feldman, MD
Laura J. Chambers, DO
Thomas Westbrook, MD
Massimo Cristofanilli, MD, attending physician, NewYork-Presbyterian Hospital; professor, medicine, Weill Cornell Medical College, Cornell University
Fred Saad, CQ, MD, FRCS, FCAHS, director, Prostate Cancer Research, Montreal Cancer Institute, Centre Hospitalier de l’Université de Montréal; full professor, Department of Surgery, Université de Montréal; uro-oncologist, Urology Department, University of Montreal Health Center
Ajay K. Nooka, MD, MPH, FACP